Purdue Pharma LP
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1892-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.purduepharma.com
Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015
Phase 3
Terminated
- Conditions
- Back Pain Lower Back Chronic
- Interventions
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 354
- Registration Number
- NCT01125917
- Locations
- 🇺🇸
Palm Beach Research Center, West Palm Beach, Florida, United States
🇺🇸Pharmquest, Greensboro, North Carolina, United States
🇺🇸Wake Research Associates, LLC, Raleigh, North Carolina, United States
To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Reformulated OXY (Wilson) (oxycodone HCl)Drug: Reformulated OXY (Totowa) (oxycodone HCl)
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 58
- Registration Number
- NCT01101321
- Locations
- 🇺🇸
Covance Clinical Research Unit Honolulu, Honolulu, Hawaii, United States
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Reformulated OXY (Totowa) (oxycodone HCl)Drug: Reformulated OXY (Wilson) (oxycodone HCl)
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 55
- Registration Number
- NCT01101308
- Locations
- 🇺🇸
Covance Clinical Research Unit Madison, Madison, Wisconsin, United States
To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Original OxyContin® (OXY) (oxycodone HCl)Drug: Reformulated OXY (oxycodone HCl)
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2010-05-11
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 92
- Registration Number
- NCT01101165
- Locations
- 🇺🇸
Covance Clinical Research Unit - Evansville, Evansville, Indiana, United States
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Reformulated OXY (oxycodone HCl)Drug: Original OxyContin® (OXY) (oxycodone HCl)
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 84
- Registration Number
- NCT01101191
- Locations
- 🇺🇸
Covance Clinical Research Unit Honolulu, Honolulu, Hawaii, United States
To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Reformulated OXY (oxycodone HCl)Drug: Original OxyContin® (OXY) (oxycodone HCl)
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2011-10-10
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 79
- Registration Number
- NCT01101178
- Locations
- 🇺🇸
Covance Clinical Research Unit Madison, Madison, Wisconsin, United States
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Reformulated OXY (oxycodone HCl)Drug: Original OxyContin® (OXY) (oxycodone HCl)
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 84
- Registration Number
- NCT01100086
- Locations
- 🇺🇸
Covance Clinical Research Unit Madison, Madison, Wisconsin, United States
A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Reformulated OXY (oxycodone HCl)Drug: Original OxyContin® (OXY) (oxycodone HCl)
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2010-05-11
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 88
- Registration Number
- NCT01100320
- Locations
- 🇺🇸
Covance Clinical Research Unit - Austin, Austin, Texas, United States
A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Reformulated OXY (oxycodone HCl)Drug: Original OxyContin® (OXY) (oxycodone HCl)
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2010-05-06
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 85
- Registration Number
- NCT01099709
- Locations
- 🇺🇸
Covance Clinical Research Unit, Honolulu, Hawaii, United States
Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee
Phase 3
Completed
- Conditions
- Chronic PainOsteoarthritis of the Knee
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 567
- Registration Number
- NCT00531427
- Locations
- 🇺🇸
Stat-Lab I, Inc., Baton Rouge, Louisiana, United States
🇺🇸Arthritis Clinic, PLLC, Jackson, Tennessee, United States
🇺🇸Coastal Pain Management, Bradenton, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath